# Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

> **NCT00073216** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 96 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** Clade B gag DNA/PLG and env DNA/PLG Microparticles
- **BIOLOGICAL:** Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant

## Key facts

- **NCT ID:** NCT00073216
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073216, "Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00073216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*